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E-mail: cmi.raoult@gmail.comIntroductionWe thank all of our reviewers for their work in 2014.
The year 2014 was a signiﬁcant change for ESCMID’s journals,
CMI and NMNI. NMNI is based in part on papers ﬁrst submitted
to CMI. NMNI has been accepted in PubMed Central, marking
the beginning of a new breakthrough for ESCMID.
ESCMID decided to change publishers and has moved from
Wiley to Elsevier. We wish to acknowledge the efforts made by
Wiley, who accompanied us during the past few years to
transform the journal.
Regarding CMI, the number of original articles submitted has
further increased, and the themed issues were diverse. The
publication of themed issues on time is extremely difﬁcult; we
wish to thank the Marseille team, which frequently helped us
through last-minute defections, thus permitting us to provide a
themed supplement to each number. The themed issues rep-
resented considerable work for the publisher and the issue
editors, and we thank them for their efforts.
The impact of CMI in the ﬁelds of infectious diseases and
microbiology is increasing: its Impact Factor is 5.182, placing it
behind Lancet Infectious Diseases, Clinical Infectious Diseases and
Emerging Infectious Diseases in the leading group of journals that
have an Impact Factor greater than 5, along with the Journal of
Infectious Diseases and AIDS.
For the ﬁrst time, we provide a listing of the 20 and the 40
most original articles cited year by year in infectious diseases
and microbiology (Tables 1A and 1B); this shows the role that
CMI is beginning to play in the most cited papers in these ﬁelds.Clinical Microbiology and Infection © 2015 European Society of CThe balance has clearly changed in recent years, with the
emergence of CMI among journals producing the most cited
original articles. Lancet Infectious Diseases has now taken the
lead in terms of the number of articles most cited. We hope
that CMI’s progress among most-cited articles will continue.
In an effort to not fall behind with articles and authors, we
have put new organization in place with Elsevier, and thanks to
their efforts, we hope to increase timeliness.
The various topics covered by CMI are shown in Table 2 and
show a reasonable balance among the journal’s different sec-
tions. Themed sections attract positive attention, particularly
when they relate to the priorities of infectious disease physi-
cians. The rates of acceptance and rejection are now stable,
with an acceptance rate of approximately 20% for original
publications and research (Fig. 1).The journal’s editorial structureCMI appears monthly and, since the end of 2013, includes peer-
reviewed manuscripts, reviews, research notes, and letters.
Each print and online issue includes a themed section. These are
organized by a guest editor and cover key topics. They consist
of three to ﬁve invited reviews on the chosen topic, an editorial
and related cover images. Table 3 shows all of the themed
sections published in 2014 and those scheduled for 2015.SubmissionsThe proportion of manuscripts submitted as original articles or
as research notes (separate from invited reviews and editorials)
is continuously increasing. In addition, these manuscripts come
from authors from a wide variety of countries (Table 4); this
shows that the journal is sought as a publication venue by many
authors, even though acceptance rates are not currently
equivalent for all countries. It is interesting to note that,Clin Microbiol Infect 2015; 21: 207–213
linical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved
http://dx.doi.org/10.1016/j.cmi.2015.02.001
TABLE 1A. The 20 most original articles cited year by year publications in infectious diseases and microbiology these last 10 years
Infectious Diseases
Rank Journal* 2004–2010 2011–YTD** # papers cited the last 4 years Evolution
1 Lancet Infectious Diseases 1% 34% 28 b
2 Clinical Infectious Diseases 35% 16% 13 a
3 Emerging Infectious Diseases 12% 10% 9 a
4 AIDS 12% 9% 8 a
5 Journal of Infectious Disease 22% 9% 7 a
6 Clinical Microbiology and Infections 0% 6% 5 b
7 JAIDS 3% 3% 2 /
8 Infection Control and Hospital Epidemiology 3% 2% 1 a
9 American Journal of Infectious Control 2% 0% 0 a
10 Journal of Antimicrobial Chemotherapy 3% 0% 0 a
Microbiology
Rank Journal* 2004–2010 2011–YTD** # papers cited the last 4 years Evolution
1 Clinical Infectious Diseases 26% 25% 20 a
2 Journal of Infectious Disease 17% 14% 11 a
3 Cell Host Microbe 7% 11% 9 b
4 ISME Journal 0% 9% 7 b
5 Plos Pathogens 5% 8% 6 b
6 Clinical Microbiology and Infections 0% 8% 6 b
7 Antimicrobial Agents and Chemotherapy 6% 5% 4 a
8 Applied Environmental Microbiology 8% 1% 1 a
9 Journal of Clinical Microbiology 4% 1% 1 a
10 Environmental Microbiology 5% 1% 1 a
*Who have had at least 1 article cited.
**16/12/2014.
Sources: Thomson Reuters
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Morocco, have now published for the ﬁrst time in CMI, thus
conﬁrming the willingness of the journal to be open to re-
searchers all over the world, including emerging countries. It isTABLE 1B. The 40 most original articles cited year by year
publications in infectious diseases and microbiology these
last 10 years
Microbiology
Rank Journal* 2004–2010 2011–YTD Evolution
1 CMI 0% 20% b
2 Applied & Environmental
Microbiology
30% 18% a
3 Journal of Clinical Microbiology 18% 13% a
4 Clinical Microbiology Reviews 0% 10% b
5 Environmental Microbiology 10% 8% a
6 Nature Reviews Microbiology 18% 8% a
7 Molecular Microbiology 3% 0% a
Infectious Diseases
Rank Journal* 2004–2010 2011–YTD Evolution
1 The Lancet Infectious Diseases 3% 45% b
2 Clinical Infectious Diseases 58% 35% a
3 Emerging Infectious Diseases 13% 13% /
4 Journal of Infectious Diseases 25% 5% a
5 Comparative Immunology
Microbiology & Infectious
Diseases
3% 3% /
6 Diagnostic Microbiology &
Infectious Diseases
0% 3% b
*Who have had at least 3 article cited.
Sources: Scopus
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectalso interesting to note that India and Republic of Korea are
among the top ten countries submitting papers to CMI. The
journal continues to make efforts to help improve papers of
high scientiﬁc quality coming from countries with cultural and
organizational difﬁculties, allowing the papers to become more
consistent with community standards.CitationsCMI achieved excellent results in the latest Journal Citation
Reports. Most signiﬁcantly, the headline 2-year Impact Factor
increased by 13% to 5.197, taking the journal above 5 for the
ﬁrst time. As can be seen in Fig. 2, CMI’s Impact Factor has
grown signiﬁcantly over the last decade and is now high above
the aggregate and median levels for both of its subjectTABLE 2. Evolution of CMI’s thematic coverage between 2011
and 2014
Theme
Ratio (%)
2011 2012 2013 2014
Bacteriology 34.40 36.62 36.02 34.10
Epidemiology 10.10 11.27 13.44 10.49
Infectious diseases 21.20 16.43 22.04 23.28
Mycology 7.70 11.74 8.60 7.54
Virology 19.30 18.31 17.74 20.33
Tropical and parasitic diseases 7.40 5.63 2.15 4.26
ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 207–213
FIG. 1. Acceptance and rejection rates for original articles and research notes since 2008. *As of 16 December 2014.
CMI Editorial 209categories. The journal is now ranked 7 of 72 journals in in-
fectious diseases and 18 of 119 in microbiology.
CMI also achieved further growth in its Eigen Factor (up6%) and
Article Inﬂuence score (up 4%), both of which are strong in-
dicators of the journal’s prestige within the scientiﬁc community.
The most cited article published in 2013 was ‘EUCAST
expert rules in antimicrobial susceptibility testing’ [1], with 52
citations to date.ReadershipOnline readership of CMI continues to grow at an impressive
rate. In 2014, total full-text downloads increased by 64% from
the prior year, reaching just under 1.8 million.Clinical Microbiology and Infection © 2015 European Society of Clinical MicrobiologyThe two most downloaded items in 2014 were guidelines:
‘European Society of Clinical Microbiology and Infectious
Diseases: update of the treatment guidance document for
Clostridium difﬁcile infection’ [2], followed by ‘ESCMID guide-
lines for the management of the infection control measures to
reduce transmission of multidrug-resistant Gram-negative
bacteria in hospitalized patients’ [3]. New publications and
older papers are both strongly represented among the most
read (Tables 5A and 5B).
The number of submitted papers has not diminished;
therefore, the number of quality papers that we want to
publish is increasing, and, despite the increased online-only
page budget, the large volume of articles makes it difﬁcult
to shorten the time from receipt to publication (Table 6).and Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 207–213
TABLE 3. Themed sections published in CMI in 2014 and
scheduled for 2015
Issue Guest editor Topic
2014
January P. Brouqui Emerging technology in tracking contagion
February M. Paul Systematic review or meta-analysis? Their
place in the evidence hierarchy
March M. Drancourt Microbe discovery: lessons from the past
April E. Bottieau Parasitic diseases and immunosuppression
May D. Raoult Emerging clones of bacterial epidemics
June M. Grobusch and
G. Greub
Bioterrorism: reality or fantasy
July G. Lina New epidemiology of S. aureus infection
August L. Kaiser and
P. Pothier
Norovirus
September G. Cornaglia and
J. M. Rolain
Carbapenemase in Enterobacteriaceae: a
worldwide emerging concern
October D. Raoult Fecal transplantation and infectious diseases
physician
November C. Pulcini and
J. L. Mainardi
Antimicrobial stewardship: an international
emergency
December A. Guido and
E. Roilides
Host genetics and infections
2015
January M. Paul Infection in the elderly
February P. Gautret Mass gathering
March G. Greub and
M. Paul
Bacteremia: the hidden killer
April M. Paul Neuraminidase inhibitors for inﬂuenza: the
new evidence
May S. Cutler Neglected zoonases
June E. Bottieau New diagnostic tools in parasitology
July T. Avsic Zupanc New vector transmitted pathogens
August F. Allerberger Acute diarrhoea: new perspective
September M. Poljak Human papillomaviruses
October G. Antonelli Infectious origin of cancer
November G. Lina and
G. Greub
Automation in clinical microbiology
December E. Tacconelli Infection control
TABLE 4. Submissions and acceptance rates by country in
2014*
Country
No. of
submissions
No. of accepted
manuscripts
Acceptance
ratio (%)
China 178 18 10
France 141 27 19
Spain 136 20 15
Italy 114 27 24
Taiwan 69 4 6
Netherlands 46 12 26
United States 46 10 22
Brazil 43 3 7
Korea, Republic of 38 2 5
India 36 1 3
United Kingdom 34 7 21
Japan 32 2 6
Switzerland 32 9 28
Germany 29 7 24
Israel 25 8 32
Turkey 24 1 4
Portugal 21 2 10
Sweden 21 6 29
Australia 19 1 5
Canada 17 5 29
Iran, Islamic
Republic of
13 0 0
Greece 11 2 18
Argentina 10 2 20
Denmark 10 5 50
Egypt 10 0 0
Austria 8 4 50
Finland 7 1 14
Poland 7 1 14
Belgium 6 1 17
Hong Kong 6 1 17
Pakistan 6 0 0
Malaysia 5 0 0
New Zealand 5 0 0
Slovenia 5 1 20
Thailand 5 4 80
Czech Republic 4 0 0
Hungary 4 0 0
Mexico 4 0 0
Norway 4 2 50
Saudi Arabia 4 1 25
Senegal 4 1 25
210 Clinical Microbiology and Infection, Volume 21 Number 3, March 2015 CMIInfection hot topics
Singapore 4 1 25
South Africa 4 0 0
Colombia 3 0 0
Iraq 3 0 0
Romania 3 1 33
Russian Federation 3 0 0
Bosnia and
Herzegovina
2 0 0
Bulgaria 2 0 0
Croatia 2 0 0
Cuba 2 0 0
Ecuador 2 1 50This category of freely accessible articles continue to
provide an immediate platform for the entire editorial board
and is thus closer to discussions in the scientiﬁc
community. This selection has been a real success since its
establishment.
Gambia 2 0 0
Iceland 2 0 0
Ireland 2 0 0
Serbia 2 0 0
Tunisia 2 0 0Future evolution and perspectives
Algeria 1 0 0
Bangladesh 1 0 0
Estonia 1 0 0
Ethiopia 1 0 0
Luxembourg 1 0 0
Madagascar 1 0 0
Morocco 1 1 100
Mozambique 1 0 0
Nicaragua 1 0 0
Nigeria 1 0 0
Oman 1 0 0
Peru 1 0 0
Philippines 1 0 0
Réunion 1 0 0
Slovakia 1 0 0
Viet Nam 1 0 0
Total 1295 202 16
*As of 16 December 2014.The percentage of rejected articles remains important
(Table 7), but some are now redirected to NMNI. In the future,
we may want to revisit the question of journal size, as well as
the creation of other associated journals.
In the journal editorial ofﬁce, we currently evaluate the
reasons for rejection of the articles to see if they correspond to
topics that might be a good ﬁt for a potential new journal. This
analysis will be presented next year.
The journal will continue to have a themed section for
each issue, as well as approximately ten original articles;Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 207–213
TABLE 5B. Most downloaded articles in 2014 YTD
Authors Article Title Volume Issue Full text accesses Ref
S. B. Debast European Society of Clinical Microbiology and Infectious Diseases: update of
the treatment guidance document for Clostridium difﬁcile infection
20 s2 23505 [2]
E. Tacconelli et al. ESCMID guidelines for the management of the infection control measures
to reduce transmission of multidrug-resistant Gram-negative bacteria in
hospitalized patients
20 s1 20508 [3]
M.E. Falagas & S. K. Kasiakou Mesh-related infections after hernia repair surgery 11 1 14226 [5]
A-P. Magiorakos et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria:
an international expert proposal for interim standard deﬁnitions
for acquired resistance
18 3 14132 [6]
E.M. Leroy et al Ebola and Marburg haemorrhagic fever viruses: major scientiﬁc advances,
but a relatively minor public health threat for Africa
17 7 13035 [13]
A. Von Graevenitz Antimicrobial therapy of infections with aerobic Gram-positive rods 7 s4 8450 [14]
B.A. Cunha The diagnostic signiﬁcance of relative bradycardia in infectious disease 6 12 8333 [7]
R. Raz Fosfomycin: an old—new antibiotic 18 1 6934 [8]
P.C Woo Then and now: use of 16S rDNA gene sequencing for bacterial
identiﬁcation and discovery of novel bacteria in clinical microbiology laboratories
14 10 6091 [11]
S. K. Singh & H.J. Girschick Lyme borreliosis: from infection to autoimmunity 10 7 5016 [4]
TABLE 5A. Most downloaded articles in 2013
Authors Article Title Volume Issue
Full text
accesses Ref
S. K. Singh & H.J. Girschick Lyme borreliosis: from infection to autoimmunity 10 7 12321 [4]
M.E. Falagas & S. K. Kasiakou Mesh-related infections after hernia repair surgery 11 1 11750 [5]
A-P. Magiorakos et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international
expert proposal for interim standard deﬁnitions for acquired resistance
18 3 9005 [6]
B.A. Cunha The diagnostic signiﬁcance of relative bradycardia in infectious disease 6 12 7507 [7]
R. Raz Fosfomycin: an old—new antibiotic 18 1 5884 [8]
S. B. Debast European Society of Clinical Microbiology and Infectious Diseases: update of the treatment
guidance document for Clostridium difﬁcile infection
20 s2 4615 [2]
D. Hill & J.P. Dubey Toxoplasma gondii: transmission, diagnosis and prevention 8 10 4478 [9]
I.M. Mackay Real-time PCR in the microbiology laboratory 10 3 4158 [10]
P.C Woo Then and now: use of 16S rDNA gene sequencing for bacterial identiﬁcation and discovery
of novel bacteria in clinical microbiology laboratories
14 10 4153 [11]
N/A Abstracts of the 22nd European Congress of Clinical Microbiology and Infectious
Diseases – Poster Sessions
18 s3 4050 [12]
FIG. 2. CMI’s Impact Factor evolution since 2002.
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TABLE 6. Year-by-year production summary
Year Volume No. of issues No. of pages No. of articles
Average no. of days from receipt at Wiley-Blackwell to publication
Online publication Print publication
2014 1 12 2527* 475* 222 226
2013 1 12 1800 316 215 218
2012 1 12 1804 333 175 183
2011 1 12 1912 349 159 170
2010 1 12 1798 319 101 217
2009 1 12 1194 200 82 90
2008 1 12 1200 206 58 66
2007 1 12 1244 232 80 88
2006 1 12 1266 242 83 91
*Clearance of article backlog at Wiley.
TABLE 7. Acceptance and rejection rates for original articles
and research notes since 2008
Year Decision made
Accepted Rejected
n Rate (%) n Rate (%)
2008 826 240 29 586 71
2009 779 208 27 571 73
2010 995 239 24 756 76
2011 1138 214 19 924 81
2012 1177 244 21 933 79
2013 1183 236 20 947 80
2014* 1170 202 17 968 82
*As of 16 December 2014.
TABLE 8. Supplements published in CMI in 2014
Authors or
editors Topic
Volume
(supplement)
and page range
Date of online
publication
Date of print
publication Sponsor
No. of
papers Ref
E. Tacconelli et al. ESCMID guidelines for the management of the
infection control measures to reduce
transmission of multidrug-resistant Gram-
negative bacteria in hospitalized patients
20 (suppl 1): 1–55 2 December 2013 January 2014 ESCMID 1 [3]
M. Bauer et al. European Society of Clinical Microbiology and
Infectious Diseases: update of the treatment
guidance document for Clostridium difﬁcile
infection
20 (suppl 2): 1–26 20 January 2014 March 2014 ESCMID 26 [15]
Edited by M. Paul ESCMID and ECMM guidelines for the
management of rare and emerging fungal
infections
20 (suppl 3): 1–98 9 March 2014 April 2014 ESCMID; ECMM 5 [16]
Edited by G. Lina European perspective on the use of linezolid
for the management of complicated skin
and soft tissue infections and nosocomial
pneumonia due to MRSA
20 (suppl 4): 1–36 28 February 2014 April 2014 Pﬁzer International
Operations
3 [17]
Edited by
R. Norrby and
M. Poljak
The impact of vaccines on public health 20 (suppl 5): 1–117 January 2014–April 2014 May 2014 ESCMID 18 [18]
Edited by M. Paul Invasive fungal infections: epidemiology and
treatment
20 (suppl 6): 1–81 January 2014–April 2014 June 2014 ESCMID 81 [19]
Edited by
G. Greub
Recommendations for the prevention and
management of infections in solid organ
transplantation (SOT): a European
perspective
20 (suppl s7): 1–130 January 2014–April 2014 September 2014 ESCMID Study Group
of Infection in
Compromised Hosts
(ESGICH)
130 [20]
TABLE 9. Evolution of processing time for treatment of
manuscripts since 2009
Disposition
Average no. of days between submission
and decision
2009 2010 2011 2012 2013 2014*
Immediate reject 17 11 9 7 4 4
Decision after
peer review
(accept, revision, reject)
63 44 31 44 74 67
Average processing time 40 27 20 29 39 35
*Up to 16 December 2013.
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CMI Editorial 213further, research notes and longer articles will be available
online. The journal also publishes supplementary issues that
reﬂect congresses organized by the ESCMID (ECCMID), or
conferences sponsored by partners; these supplements also
enjoy a relatively large number of citations (Table 8). The
supplementary issues have been managed by the Editorial
Board since 2010.Workﬂow—evolution since 2009The current processing time for manuscripts has continued to
improve since 2009 (Table 9). In 2014, this averaged 35 days;
this is broken down into 4 days for immediate rejection and 67
days for a decision of acceptance, revision or rejection after
peer review, which, at present, appears reasonable.ConclusionThe ambitions of CMI are to reﬂect the academic activities of
the ESCMID, and more generally of the world of infectious
diseases and clinical microbiology, and to attract the best
publications and reviews within the ﬁeld. It also aims to attract
attention to emerging ﬁelds and to speciﬁc important topics or
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